
|Articles|April 30, 2007
AstraZeneca buying MedImmune
British pharmaceutical giant AstraZeneca announced it is acquiring Gaithersburg, Md.-based MedImmune for $15.6 billion.
Advertisement
British pharmaceutical giant AstraZeneca announced it is acquiring Gaithersburg, Md.-based MedImmune for $15.6 billion. The deal, which is expected to close in June, will allow AstraZeneca to gain a presence in the increasingly lucrative vaccines market. It will also reportedly increase the company's proportion of biotechnology drugs in its pipeline to 27%, from 7%, and enlarge its total pipeline by 45 projects, to 163 projects.
To see more Hot off the Press news articles,
To go to the Drug Topics homepage,
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
ICER Report Finds GLP-1s Are Cost-Effective But Warns of Budget Strain
2
New Study Finds Compounded GLP-1s Remain Robust Despite End of Shortages
3
Postpartum Mothers Favor Bedtime Stopping Rule Over Stricter Chrononutrition Approaches
4
What’s Next for Pneumococcal Vaccination? An Expert Weighs In
5






























